| Description: | The Recover offers reporting on trending news topics about addiction and mental health. A team of experienced journalists write non-bias news about major health news issues. A New light for moms struggling with postpartum depression has surfaced Tuesday. The Food and Drug Administration has finally approved its first drug aimed directly at treating this condition, called Brexanolone, or Zulresso.
Brexanolone is a miracle because it is a synthetic form of the hormone allopregnanolone, a progesterone derivative, in it. Typically the hormone increases during a women’s pregnancy and then depletes rapidly after the woman gives birth, a primary reason for why most women develop postpartum depression.
“This can potentially transform women’s lives and that of their families,” announced Dr. Steve Kanes, chief medical officer of Sage Therapeutics, the Cambridge, Mass., biopharmaceutical company that developed Brexanolone. “It’s not just the mother who suffers when there’s postpartum depression. It’s the newborn. It’s the other people in their family.” |
